Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
about
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Trends in the incidence and survival of multiple myeloma in South East England 1985-2004Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications.Multiple myeloma in the older adult: better prospects, more challenges.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Front line treatment of elderly multiple myeloma in the era of novel agents.Uncommon, sinister vertebral fracture: early-onset multiple myelomaMore frequent IgD and reduced CD200 expression in Chinese patients younger than 50 years old with multiple myeloma: a multicenter analysis.A rare case of renal recovery in a young patient with multiple myelomaHematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.Treatment of multiple myeloma in the elderly: realities and hopes.Advances in multiple myeloma therapy during two past decades.Reconstruction of multiple myeloma lesions around the pelvis and acetabulum.Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.Defining and treating high-risk multiple myeloma.Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India.Management of high-risk Myeloma: an evidence-based review of treatment strategies.Current Review on High-Risk Multiple Myeloma.Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.Treatment of Relapsed/Refractory Multiple Myeloma.Management of Elderly Patients with Plasma Cell Myeloma.Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.Aggressive plasmablastic multiple myeloma in a 42-year-old: is inflammatory bowel disease or infliximab treatment to be blamed?Renal status of multiple myeloma patients in ibadan, Nigeria.Multiple myeloma in the very old: an IASIA conference report.Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups.Autologous transplant in multiple myeloma with an augmented conditioning protocol.Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.
P2860
Q30486842-CD6CA4DB-4725-4F96-87FF-31D735546B00Q30595175-B7B68EEF-26A4-4425-97DD-F0C032ABCC04Q33535489-11DF6360-5630-4B81-BA79-325461D4DA4CQ33907261-47BA6437-E505-4657-BAD0-092798590555Q34031129-16BF5062-938D-49C9-BF9B-287702CF3935Q34241661-01699878-798A-4489-B3FC-A4CD945AFE15Q34372086-31263F34-9AED-44C8-A799-F94B8AC28C7CQ34993904-9E12C807-DD6F-4B2F-900E-6125EE7EE429Q35569350-A97788C4-D525-44C7-8779-7A5DD9F1811CQ35802414-08997F87-FFC4-45C0-B7A8-8A5292A5BEADQ36848023-A152571B-2DA8-4015-A485-F65DD4E993DFQ37029350-47D8CDB5-65C6-47EF-A5EB-8BE8CC49E10FQ37037265-220253B6-F084-448D-B82F-B55ABE854C61Q37303213-D0202819-2ACC-4E27-A15D-5EEFAE8AE38AQ37308586-2218EF30-87A0-4370-A8ED-986FD7C04594Q37412952-EAC51DC6-10C1-4B6E-B2D4-3A3A96167E89Q37556243-EFFC4A83-EB16-4BF9-BF03-BD552A87D984Q37651875-1C9592ED-EE69-466C-82A1-7E95C58F2C3EQ37809535-69D3A78D-EF3C-4855-9E03-81414401397DQ38248293-6677BB87-AFB0-496B-BC36-37484100A8D8Q38261214-83FBD7A0-9413-48F7-8B80-A5E08AB17A5FQ38367654-ED6DEF3D-BCAB-44AF-B96B-55BB0E639753Q38564926-A2CE0E0A-A378-4C6C-8F42-710D13F09E9CQ38757989-3E8074A9-DE80-4808-9848-5F91557C1159Q38874675-E9678575-82F2-4BA0-8583-977C6A2A9F3AQ38895167-EFDFB873-7E78-4E7A-B722-B4E7C1D871ABQ38947433-397FABF8-20A3-40CD-8967-919116E28A4CQ38970597-7915881B-7C44-42A1-876E-6233245BA4B7Q39001325-FD65B8A6-FCC6-43FE-9654-8D0429E920C9Q39134450-A28D4310-AB69-450E-8826-D7D0D4C21393Q39210735-7BAA55CD-3081-4AA3-B0B3-D4FBE6A6A698Q40095723-0A140865-63E0-4ED5-8DB9-AEC78068F6CDQ42553287-42670DB9-D8FC-4D5B-A69B-07836C20FEFCQ42748910-4348EB65-4180-44B4-A3A4-41E7C5D46CE0Q43242121-CD987272-00D0-42AD-AE8C-7B224F2064FDQ44641465-40AEB0EA-B32F-4C7C-B232-CB3B5F22C2E3Q44687339-E73885CF-CA00-41BC-B080-28F3F7146C2CQ45114730-92A55A15-8EC2-465D-9D73-B96FDAFF8354Q47300966-0B3684B3-8DDD-4429-8C8D-284AF9A65B18Q47776224-A144B089-99EC-4912-9FDB-36A2393F7744
P2860
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Myeloma in patients younger th ...... ational Myeloma Working Group.
@ast
Myeloma in patients younger th ...... ational Myeloma Working Group.
@en
Myeloma in patients younger th ...... ational Myeloma Working Group.
@nl
type
label
Myeloma in patients younger th ...... ational Myeloma Working Group.
@ast
Myeloma in patients younger th ...... ational Myeloma Working Group.
@en
Myeloma in patients younger th ...... ational Myeloma Working Group.
@nl
prefLabel
Myeloma in patients younger th ...... ational Myeloma Working Group.
@ast
Myeloma in patients younger th ...... ational Myeloma Working Group.
@en
Myeloma in patients younger th ...... ational Myeloma Working Group.
@nl
P2093
P2860
P50
P1433
P1476
Myeloma in patients younger th ...... ational Myeloma Working Group.
@en
P2093
Brian G M Durie
Chaim Shustik
Douglas Joshua
Ingemar Turesson
Jan Westin
Jean-Luc Harousseau
Joan Blade
John Crowley
Kazuyuki Shimizu
Mario Boccadoro
P2860
P304
P356
10.1182/BLOOD-2007-03-081018
P407
P50
P577
2008-02-11T00:00:00Z